Accenture and the National Institute for Bioprocessing Research and Training (NIBRT) will launch a new research collaboration that expedites global production of life-saving treatments and medicines.
The new “Biotech Digital Twin” project will be supported by Accenture resources including two new life sciences jobs as well as funding from both Accenture and Enterprise Ireland. The project will create a digital twin, or virtual representation, that will serve as a real-time digital counterpart of the biology of the manufacturing process. The project team will then compare the results from the computer simulated experiments to those in the real world, at NIBRT’s state-of-the-art laboratories, to determine the accuracy of the biology of the digital twin and work to continuously improve the model.
The treatment was developed by Calliditas and will be marketed by Stada
The European Commission (EC) has granted conditional marketing authorisation for Kinpeygo (budesonide) capsules for the treatment of primary immunoglobulin A nephropathy (IgAN).
The treatment involves adults at risk of rapid disease progression with a specific urine protein-to-creatinine ratio.